Skip to content

AXSOME THERAPEUTICS, INC.: 10-K filed 2020-03-12

What AXSOME THERAPEUTICS, INC. reported in its annual report filed 2020-03-12 (fiscal FY 2019): 28 published measures, 90 facts as tagged in accession 0001558370-20-002573.

This filing

Form
10-K (annual report)
Filed
2020-03-12
Fiscal period
fiscal FY 2019
Accession
0001558370-20-002573 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AXSOME THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-12-31220,549,760USD
At 2018-12-3115,379,279USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-12-3141,827,371USD
At 2018-12-3114,441,358USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-12-31178,722,389USD
At 2018-12-31937,921USD
At 2017-12-3116,717,223USD
At 2016-12-3121,571,451USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-10-01 to 2019-12-31-24,806,984USD92
2019-01-01 to 2019-12-31-68,345,186USD365
2019-07-01 to 2019-09-30-19,135,612USD92
2019-04-01 to 2019-06-30-13,762,214USD91
2019-01-01 to 2019-03-31-10,640,376USD90
2018-10-01 to 2018-12-31-9,597,015USD92
2018-01-01 to 2018-12-31-30,965,464USD365
2018-07-01 to 2018-09-30-8,281,974USD92
2018-04-01 to 2018-06-30-8,280,916USD91
2018-01-01 to 2018-03-31-4,805,559USD90
2017-01-01 to 2017-12-31-28,943,392USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-46,375,059USD365
2018-01-01 to 2018-12-31-30,053,701USD365
2017-01-01 to 2017-12-31-26,471,652USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-01-01 to 2019-12-3116,121USD365
2018-01-01 to 2018-12-3132,696USD365
2017-01-01 to 2017-12-319,898USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-12-31252,388,605USD365
2018-01-01 to 2018-12-3110,034,016USD365
2017-01-01 to 2017-12-3123,884,176USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-16,121USD365
2018-01-01 to 2018-12-31-32,696USD365
2017-01-01 to 2017-12-31-9,898USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-12-31-175,895,493USD
At 2018-12-31-107,550,307USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2019-01-01 to 2019-12-310USD365
2018-01-01 to 2018-12-310USD365
2017-01-01 to 2017-12-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-12-3130,623USD
At 2018-12-3151,832USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-01-01 to 2019-12-316,115,160USD365
2018-01-01 to 2018-12-311,754,974USD365
2017-01-01 to 2017-12-312,072,210USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-67,245,097USD365
2018-01-01 to 2018-12-31-32,846,577USD365
2017-01-01 to 2017-12-31-27,164,307USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-12-31220,379,262USD
At 2018-12-3115,215,102USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-12-3124,494,745USD
At 2018-12-3110,821,938USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-12-3110,943,325USD
At 2018-12-313,687,245USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-10-01 to 2019-12-3124,428,170USD92
2019-01-01 to 2019-12-3167,245,097USD365
2019-07-01 to 2019-09-3018,947,235USD92
2019-04-01 to 2019-06-3013,448,219USD91
2019-01-01 to 2019-03-3110,421,473USD90
2018-10-01 to 2018-12-319,450,315USD92
2018-01-01 to 2018-12-3132,846,577USD365
2018-07-01 to 2018-09-308,243,459USD92
2018-04-01 to 2018-06-307,989,593USD91
2018-01-01 to 2018-03-317,163,210USD90
2017-01-01 to 2017-12-3127,164,307USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-01-01 to 2019-12-3153,647,067USD365
2018-01-01 to 2018-12-3123,495,055USD365
2017-01-01 to 2017-12-3119,957,616USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-12-3136,933,217shares
At 2018-12-3130,087,213shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-12-31354,614,189USD
At 2018-12-31108,485,219USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2019-12-31139,875USD
At 2018-12-31112,345USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-12-31413,095USD
At 2018-12-311,246,360USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-68,345,186USD365
2018-01-01 to 2018-12-31-30,965,464USD365
2017-01-01 to 2017-12-31-28,943,392USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-01-01 to 2019-12-3113,598,030USD365
2018-01-01 to 2018-12-319,351,522USD365
2017-01-01 to 2017-12-317,206,691USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2019-01-01 to 2019-12-3137,330USD365
2018-01-01 to 2018-12-3148,935USD365
2017-01-01 to 2017-12-3142,557USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2019-01-01 to 2019-12-311,287,506USD365
2018-01-01 to 2018-12-31771,966USD365
2017-01-01 to 2017-12-31865,278USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2019-01-01 to 2019-12-31238,233,817USD365
2018-01-01 to 2018-12-3112,881,321USD365
2017-01-01 to 2017-12-3123,677,341USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-317,256,080USD365
2018-01-01 to 2018-12-31251,789USD365
2017-01-01 to 2017-12-31-645,717USD365

Inspect the source

Entity
AXSOME THERAPEUTICS, INC. / CIK 0001579428
Captured
2026-09-19T11:19:11.812Z
SEC response SHA-256
bb534249e79901f14ef56a7cde4d7cfc00d4e7cc31cc09f237146d8a497ea5fc

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001579428.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))